- Home
- NBTX vs INBX Comparison
NBTX vs INBX Comparison
Compare NBTX & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- INBX
- Stock Information
- Founded
- NBTX 2003
- INBX 2010
- Country
- NBTX France
- INBX United States
- Employees
- NBTX N/A
- INBX 161
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- INBX Health Care
- Exchange
- NBTX Nasdaq
- INBX Nasdaq
- Market Cap
- NBTX 178.7M
- INBX 168.1M
- IPO Year
- NBTX 2020
- INBX 2020
- Fundamental
- Price
- NBTX $3.29
- INBX $11.47
- Analyst Decision
- NBTX Strong Buy
- INBX Hold
- Analyst Count
- NBTX 1
- INBX 1
- Target Price
- NBTX $8.00
- INBX N/A
- AVG Volume (30 Days)
- NBTX 11.4K
- INBX 144.3K
- Earning Date
- NBTX 04-02-2025
- INBX 05-08-2025
- Dividend Yield
- NBTX N/A
- INBX 7.40%
- EPS Growth
- NBTX N/A
- INBX N/A
- EPS
- NBTX N/A
- INBX 112.62
- Revenue
- NBTX N/A
- INBX $200,000.00
- Revenue This Year
- NBTX N/A
- INBX N/A
- Revenue Next Year
- NBTX $277.81
- INBX N/A
- P/E Ratio
- NBTX N/A
- INBX $0.10
- Revenue Growth
- NBTX N/A
- INBX N/A
- 52 Week Low
- NBTX $2.76
- INBX $10.80
- 52 Week High
- NBTX $7.51
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- NBTX 46.34
- INBX 34.68
- Support Level
- NBTX $3.28
- INBX $10.81
- Resistance Level
- NBTX $3.53
- INBX $12.06
- Average True Range (ATR)
- NBTX 0.18
- INBX 1.00
- MACD
- NBTX 0.00
- INBX -0.19
- Stochastic Oscillator
- NBTX 46.48
- INBX 18.52
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.